Iatrogenic cataracts in ROP eyes
Indian Journal of Ophthalmology · 2023
DOI: 10.4103/ijo.ijo_2744_23 ↗Kurz gefasst
Editorial in der Zeitschrift Indian Journal of Ophthalmology, 2023. Verfasst von M Vanathi. Beteiligte Einrichtung: Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Del…. Hauptthemen laut MEDLINE: Cataract, Retinopathy of Prematurity. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Retinopathy of prematurity (ROP) and cataract are now considered to be the most common causes of visual impairment in children.[1] In India, preterm infants born before 34 weeks of gestational age with birth weight less than 2000 g and those born after 34 weeks of gestational age with >2000 g of birth weight and with high-risk factors have been identified as being at risk for ROP.[2] The incidence of cataract in the preterm, low-birthweight infants has been reported to be 0.97%–1.9%.[3,4] The etiopathogenesis of cataract in cases with ROP is multifactorial, being related to systemic factors, complicated cataract, posttreatment (following cryotherapy, laser [due to thermal injury, persistent tunica vasculosa lentis, anterior segment ischemia, uveal effusion], post-intravitreal anti-vascular endothelial growth factor [VEGF] injections, after lens-sparing vitrectomy for ROP surgery), and steroid-induced cataracts.[5] ROP, being a vasoproliferative disorder, intravitreal anti-VEGF injections are now being increasingly adopted, either as monotherapy or along with laser therapy for its treatment, with the safety and efficacy of these agents in preterm infants with ROP being uncertain.[6] Bilateral total cataract following laser treatment for aggressive posterior ROP can further complicate the situation, hindering post-laser assessment in these eyes.[7] Cataract incidence in laser-treated ROP is reported to vary between 0.003% and 6%.[5] Prominent anterior vasculosa lentis, inadvertent burns placement on the iris or ciliary body, and confluent laser therapy have been identified as risk factors leading to cataract in ROP eyes in post-laser situations. Intravitreal injection administered by those unfamiliar with the difference in the anatomy of these small eyes can complicate the situation with mechanical lens. Cataract formation in these ROP eyes has been reported to occur due to inadvertent lens touch with the injection needle.[8] The intravitreal injection in these preterm ROP eyes is recommended to be given with the needle tip directed posteriorly toward the optic disc. With the sclera in infants being more deformable than in adults, localized deformation at the injection site can also result in zonulopathy and posterior capsular damage. Suspected preexisting posterior capsular dehiscence has also been reported in these eyes.[9] Cataract formation in post-intravitreal anti-VEGF eyes which have not experienced lens injury has been attributed to the toxicity to the drug molecule itself.[5] The SAFER [(S)hort needle (4-mm length), (A)ntiseptic/antibiotic (5% to 10% topical betadine), (F)ollowup (48 to 72 hours post-injection), (E)xtra attention to detail (clean environment, injection site 0.75 mm to 1.0 mm posterior to limbus), and (R)echeck (1 to 2 weeks following injection and until mature vascularization or laser) protocol is a safe way to inject anti-VEGF and to monitor ROP progression following injection.[10] The SAFER protocol is a safe way to inject anti-VEGF and to monitor ROP progression following injection. A thorough ocular ophthalmologic examination is mandatory in premature infants for ROP screening as many other ocular comorbidities have also been identified in these small eyes.[11,12] Iatrogenic cataract occurrence as a result of post-laser, post–anti-VEGF injection therapy for ROP management is now being increasingly recognized as an emerging morbidity complicating the already existing challenges of anatomic differences, preoperative retina status, pupillary dilatation, neovascularization of iris in aggressive posterior ROP, fundus examination, amblyopia, and follow-up in these ROP eyes. Additional posterior barrage laser in type 1 zone 2 ROP, surgical outcomes in aggressive ROP (AROP), status of RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted; CCL5) in ROP suggests its possible role in pathobiology, Children’s Hospital of Philadelphia ROP (CHOP ROP) model in the prediction of type 1 ROP, fetal hemoglobin in the development of ROP, and efficacy and safety of posterior to the ridge laser in zone 2 stage 3 ROP with plus disease are some of the updates in ROP that are being discussed in the current issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R P Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Zitieren
APA
Vanathi, M. (2023). Iatrogenic cataracts in ROP eyes. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2744_23
Vancouver
Vanathi M. Iatrogenic cataracts in ROP eyes. Indian Journal of Ophthalmology. 2023. doi:10.4103/ijo.ijo_2744_23
BibTeX
@article{Vanathi2023,
author = {Vanathi, M},
title = {Iatrogenic cataracts in ROP eyes},
journal = {Indian Journal of Ophthalmology},
year = {2023},
doi = {10.4103/ijo.ijo_2744_23}
}
EUVIMED